La paralysie supranucléaire progressive : nouveaux concepts cliniques et neuropathologiques

Barsottini, 2010, Progressive supranuclear palsy: new concepts, Arq Neuropsiquiatr, 68, 938, 10.1590/S0004-282X2010000600020 Bensimon, 2009, Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study, Brain, 132, 156, 10.1093/brain/awn291 Borroni, 2008, Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy, Neurology, 71, 1796, 10.1212/01.wnl.0000335941.68602.39 Bouchard, 2011, Tauopathies: one disease or many?, Can J Neurol Sci, 38, 547, 10.1017/S0317167100012087 Constantinescu, 2009, Levels of brain related proteins in cerebrospinal fluid: an aid in the differential diagnosis of parkinsonian disorders, Parkinsonism Relat Disord, 15, 205, 10.1016/j.parkreldis.2008.05.001 Cordato, 2001, Corticobasal syndrome with tau pathology, Mov Disord, 16, 656, 10.1002/mds.1124 Daniele, 1999, Zolpidem in progressive supranuclear palsy, N Engl J Med, 341, 543, 10.1056/NEJM199908123410721 Eckert, 2005, FDG PET in the differential diagnosis of parkinsonian disorders, Neuroimage, 26, 912, 10.1016/j.neuroimage.2005.03.012 Engel, 1996, Treatment of progressive supranuclear palsy with amitriptyline: therapeutic and toxic effects, J Am Geriatr Soc, 44, 1072, 10.1111/j.1532-5415.1996.tb02940.x Gold, 2012, Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy, Neuropsychiatr Dis Treat, 8, 85 Hodges, 2004, Clinicopathological correlates in frontotemporal dementia, Ann Neurol, 56, 399, 10.1002/ana.20203 Josephs, 2008, Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy, Curr Opin Neurol, 21, 688, 10.1097/WCO.0b013e3283168ddd Karakaya, 2012, Treatment options for tauopathies, Curr Treat Options Neurol., 14, 126, 10.1007/s11940-012-0168-7 Kimura, 2011, Brain perfusion differences in Parkinsonian disorders, Mov Disord, 26, 2530, 10.1002/mds.23915 Lang, 2005, Treatment of progressive supranuclear palsy and corticobasal degeneration, Mov Disord, 20, S83, 10.1002/mds.20545 Liepelt, 2010, Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis, Alzheimer Dement, 6, 70, 10.1016/j.jalz.2009.04.1231 Litvan, 1996, Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop, Neurology, 47, 1, 10.1212/WNL.47.1.1 Litvan, 2001, Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy, Neurology, 57, 467, 10.1212/WNL.57.3.467 Longoni, 2011, MRI measurements of brainstem structures in patients with Richardson's syndrome, progressive supranuclear palsy-parkinsonism, and Parkinson's disease, Mov Disord, 26, 247, 10.1002/mds.23293 Mayr, 2002, Zolpidem in progressive supranuclear palsy, Eur J Neurol, 9, 184, 10.1046/j.1468-1331.2002.0354g.x Morelli, 2011, MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study, Neurology, 77, 1042, 10.1212/WNL.0b013e31822e55d0 Morris, 2002, Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy, Brain, 125, 969, 10.1093/brain/awf109 Müller, 1997, Expression of microtubule-associated proteins MAP2 and tau in cultured rat brain oligodendrocytes, Cell Tissue Res, 288, 239, 10.1007/s004410050809 Nath, 2003, Clinical features and natural history of progressive supranuclear palsy: a clinical cohort study, Neurology, 60, 910, 10.1212/01.WNL.0000052991.70149.68 O'Sullivan, 2008, Clinical outcomes of progressive supranuclear palsy and multiple system atrophy, Brain, 131, 1362, 10.1093/brain/awn065 O'Sullivan, 2010, Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy, Mov Disord, 25, 638, 10.1002/mds.22902 Park, 2009, Functional brain imaging in pure akinesia with gait freezing: [18F] FDG PET and [18F] FP-CIT PET analyses, Mov Disord, 24, 237, 10.1002/mds.22347 Poujois, 2007, Effect of gabapentin on oculomotor control and parkinsonism in patients with progressive supranuclear palsy, Eur J Neurol, 14, 1060, 10.1111/j.1468-1331.2007.01687.x Quattrone, 2008, MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy, Radiology, 246, 214, 10.1148/radiol.2453061703 Romano, 2001, Procerus sign in progressive supranuclear palsy, Neurology, 57, 1928, 10.1212/WNL.57.10.1928 Ros, 2005, Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1, Ann Neurol., 57, 634, 10.1002/ana.20449 Santacruz, 1998, Progressive supranuclear palsy: a survey of the disease course, Neurology, 50, 1637, 10.1212/WNL.50.6.1637 Seppi, 2010, Brain magnetic resonance Imaging techniques in the diagnosis of parkinsonian syndromes, Neuroimaging Clin N Am, 20, 29, 10.1016/j.nic.2009.08.016 Stamelou, 2010, Rational therapeutic approaches to progressive supranuclear palsy, Brain, 133, 1578, 10.1093/brain/awq115 Srulijes, 2012, Fluorodeoxyglucose positron emission tomography in Richardson's syndrome and progressive supranuclear palsy-parkinsonism, Mov Disord, 27, 151, 10.1002/mds.23975 Varrone, 2007, Identification by [99mTc]ECD SPECT of anterior cingulate hypoperfusion in progressive supranuclear palsy, in comparison with Parkinson's disease, Eur J Nucl Med Mol Imaging, 34, 1071, 10.1007/s00259-006-0344-7 Williams, 2005, Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism, Brain, 128, 1247, 10.1093/brain/awh488 Williams, 2006, Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau, Intern Med J, 36, 652, 10.1111/j.1445-5994.2006.01153.x Williams, 2007, Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy, Mov Disord, 22, 2235, 10.1002/mds.21698 Williams, 2007, Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome, Brain., 130, 1566, 10.1093/brain/awm104 Williams, 2008, J. Clifford Richardson and 50 years of progressive supranuclear palsy, Neurology, 70, 566, 10.1212/01.wnl.0000286938.39473.0e Williams, 2009, Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges, Lancet Neurol, 8, 270, 10.1016/S1474-4422(09)70042-0